Product
Mirikizumab
Aliases
LY3074828, Mirikizumab Autoinjector, Mirikizumab IV, Mirikizumab - IV (5 other aliases)
20 clinical trials
6 indications
Indication
ulcerative colitisIndication
HealthyIndication
Ulcerative ColitisIndication
PsoriasisIndication
Inflammatory Bowel DiseaseIndication
Crohn's diseaseClinical trial
A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Healthy Chinese SubjectsStatus: Completed, Estimated PCD: 2020-12-11
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)Status: Active (not recruiting), Estimated PCD: 2021-11-03
Clinical trial
A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With MirikizumabStatus: Recruiting, Estimated PCD: 2024-12-09
Clinical trial
A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Japanese and Caucasian Healthy SubjectsStatus: Completed, Estimated PCD: 2018-07-16
Clinical trial
Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2019-10-28
Clinical trial
Relative Bioavailability of a Mirikizumab Test Formulation Compared to the Reference Formulation in Healthy SubjectsStatus: Completed, Estimated PCD: 2021-01-11
Clinical trial
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative ColitisStatus: Completed, Estimated PCD: 2023-03-15
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)Status: Active (not recruiting), Estimated PCD: 2021-01-21
Clinical trial
A Phase 1, Single-Dose Study to Assess the Relative Bioavailability, Absolute Bioavailability, and Tolerability of LY3074828 Formulations in Healthy SubjectsStatus: Completed, Estimated PCD: 2018-04-03
Clinical trial
A Bioequivalence Study of Injections of Mirikizumab Solution Using an Investigational 1-mL Pre-Filled Syringe and an Investigational 1-mL Autoinjector in Healthy ParticipantsStatus: Completed, Estimated PCD: 2021-05-17
Clinical trial
A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2030-07-30
Clinical trial
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3Status: Recruiting, Estimated PCD: 2026-07-07
Clinical trial
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2025-01-02
Clinical trial
A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2026-07-20
Clinical trial
A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2027-07-18
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's DiseaseStatus: Completed, Estimated PCD: 2023-08-23
Clinical trial
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3Status: Terminated, Estimated PCD: 2022-02-07
Clinical trial
A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using an Investigational 1-mL Autoinjector and Mirikizumab Test Solution Formulation Using an Investigational 1-mL Autoinjector in Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-02-20
Clinical trial
A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using Investigational 1-mL and 2-mL Prefilled Syringes and Mirikizumab Test Solution Formulation Using Investigational 1-mL and 2-mL Prefilled Syringes in Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-05-25
Clinical trial
A Bioequivalence Study of Subcutaneous Injections of Citrate-Free Mirikizumab Solution Using a 1-mL Autoinjector and an Investigational 2-mL Autoinjector in Healthy ParticipantsStatus: Not yet recruiting, Estimated PCD: 2024-11-01